North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
|Articles|December 1, 1996
The American Journal of Managed Care
- November/December 1996
- Volume 2
- Issue 11
Six HMOs in Search of a Study: Comments on Two Papers by Horn et al
Author(s)Mark S. Blumberg, MD
Advertisement
Articles in this issue
almost 30 years ago
The Year in Reviewalmost 30 years ago
Childhood Immunizations: Beyond HEDISalmost 30 years ago
Implementation of a Clinical Pathway for Cesarean Sectionalmost 30 years ago
The Economic and Health-Related Quality of Life Impact of Epilepsyalmost 30 years ago
Telecomputing as a Tool to Increase Consumer Participation in Managed Carealmost 30 years ago
Disease Management: Has Anyone Managed to Make It Work?Advertisement
Related to this article
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
A follicular lymphoma survivor shares axi-cel CAR T-cell therapy highs, experiences with severe CRS and neurotoxicity, and why access to care and clinical trials improve quality of life.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Advertisement
Advertisement
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
4
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
5